Diaper Rash

40,000 American Shoppers Voted Boudreaux's Butt Barrier® Ointment as Most Innovative Product of 2024 in Baby Care TARRYTOWN, N.Y., Feb. 9, 2024 /PRNewswire/ -- Boudreaux's Butt Paste's Butt Barrier® Ointment has been honored as a recipient of the prestigious 2024 Product of the Year USA Award, recognized as the top product in the baby care category based on a survey of 40,000 people by Kantar. The Product of the Year USA Award is one of the most respected honors in the consumer goods industry, celebrating excellence in product innovation and quality. Boudreaux's Butt Barrier® Ointment stood out among a competitive field of products, showcasing its effectiveness in preventing diaper rash while maintaining the highest standards of safety and reliability. Continue Reading Product of the Year Logo Developed with the utmost care and expertise by Boudreaux's Butt Paste's team of experts, Boudreaux's Butt Barrier® Ointment offers a unique blend of ingredients designed to create a protective barrier against wetness and irritation. The Butt Barrier® Ointment is clinically tested, hypoallergenic, fragrance free and has been accepted by the National Eczema Association. Its gentle yet effective formula is safe for use at every diaper change providing peace of mind for parents, ensuring their little ones stay comfortable and happy. Recommended by pediatricians and trusted by parents, Boudreaux's Butt Paste® is relied upon to soothe and alleviate diaper rash discomfort and has been a staple for parents for over 40 years. "As we celebrate this remarkable achievement, we remain committed to our mission of helping parents care for their little ones with confidence and peace of mind," said Tim Crowley, Associate Director of Pediatrics at Prestige Brands. "This recognition is a testament to our dedication to providing parents with the best possible solutions for their baby's delicate skin. We are immensely grateful to our customers for their trust and support." As a globally recognized symbol of endorsement, Product of the Year has been active in the United States for 16 years and boasts over 30 years of operation worldwide. Serving as a reliable guide for shoppers, it aids in navigating the plethora of new products available, both online and in-store. In an era where consumers are increasingly mindful of their budgets and make discerning choices, the Product of the Year red seal serves as a distinctive marker. This mark assists consumers in identifying the most exceptional new products that excel in areas such as thoughtful design, quality, and innovation, cutting through the clutter on store shelves. For further information about Boudreaux's Butt Paste®, visit buttpaste.com. Additional details on the full list of 2024 Product of the Year Winners can be found at productoftheyearusa.com, along with on Instagram, Facebook and X (formerly Twitter) at #POYUSA2024. About Boudreaux's Butt Paste® Created by pharmacist and father of four, George Boudreaux, in 1978, Boudreaux's Butt Paste ® was born from the need for an effective and safe solution to treat diaper rash. Created specifically for parents who don't want to settle for anything less than the best, it uses a combination of efficacious ingredients to be fast acting without being harsh on a baby's skin. Boudreaux's Butt Paste ® is formulated without harmful ingredients and is free-from dyes, parabens, preservatives, and talc. Parents rely on this trusted and pediatrician-recommend diaper rash line to help soothe and relieve rash discomfort from the first use and beyond. Boudreaux's ® is part of C.B. Fleet Company, Incorporated, a Prestige Brands Company. About Product of the Year Product of the Year is the largest consumer-voted award for product innovation. Established over 30 years ago, POY currently operates in over 40 countries with the same purpose: Guide consumers to the best products in their market and reward manufacturers for quality and innovation. Product of the Year winners are backed by the votes of 40,000 consumers in a national representative study conducted by research partner Kantar, a global leader in consumer research. The award is a powerful merchandising program for marketers proven to increase product sales, distribution, and awareness. Winning products are announced in February each year and receive the right to use the Product of the Year logo in marketing communications for two years. For more information, visit productoftheyearusa.com. About Kantar Kantar is the world's leading marketing data, insight and consultancy company. We know more about how people live, feel, shop, vote, watch and post worldwide than any other company. Working across the entire sales and marketing lifecycle, we help brands uncover growth in an extraordinary world. Kantar is part of WPP and its services are employed by over half of the Fortune 500 companies in 100 countries. SOURCE Boudreaux's Butt Paste

PITTSBURGH, Jan. 24, 2024 /PRNewswire/ -- "I'm a mother and nurse and I wanted to create a new cream to treat diaper rash for my children as well as help my mother who suffers from pressure sores," said an inventor, from Springfield, Mass., "so I invented the OATESSLEUM. My design offers an effective topical treatment and barrier cream to reduce skin irritations." The invention provides an improved treatment for diaper rash and other rashes/skin conditions. In doing so, it offers an alternative to traditional ointments and creams. As a result, it helps prevent skin breakdown and it would maintain skin integrity. The invention features an effective formula that is easy to apply so it is ideal for parents with babies, elderly and disabled individuals who are bed- or chair-bound, hospitals, nursing homes, etc. The original design was submitted to the National sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 22-CPC-769, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at . SOURCE InventHelp

THURSDAY, Jan. 18, 2024 -- Fetal exposure to opioids may change a baby's immune system, triggering a rise in risks for eczema and asthma through early childhood, new research shows. Children born to women who used opioids during pregnancy had much higher rates of eczema, as well as conditions such as "diaper rash," during infancy, Australian researchers report. These children also went on to have significantly higher odds for asthma and eczema by the age of 5. The findings echo those seen in prior animal studies and suggest that "prenatal opioid exposure may have a long-term impact on the immune system and child health," the researchers said. The study was led by Erin Kelty of the University of Western Australia, in Crawley, and was published Jan. 17 in the journal JAMA Network Open . As Kelty's team relate, rodent studies have already shown that fetal exposure to opioids "may result in immune priming, such that the immune system overreacts to subsequent and later immune activation." The new study focused on data on outcomes for more than 400,000 children born in Western Australia between 2003 and 2018. Of those births, 1,656 children were diagnosed as having been exposed to opioids in the womb. Crunching the numbers, Kelty's team found that short-term (just after delivery) risks for eczema and dermatitis (issues such as diaper rash) soared for babies exposed to opioids. The risk for eczema/dermatitis in these infants rose almost 12-fold among these infants compared to unexposed babies. That increase in risk did subside as children aged, but remained high. For example, children who'd been prenatally exposed to opioids were still 47% more likely to develop eczema or dermatitis by the age of 5, compared to kids without such exposures. The authors stressed that this effect was observed solely among children whose moms had received opioids in conjunction with an opioid use disorder, not to help ease pain. Asthma risks also rose in kids exposed to opioids in utero: These children had 44% higher odds of developing the respiratory disorder by age 5, compared to unexposed children. The study found no link between exposure to opioids in the womb and the risk for other autoimmune disorders, such as type 1 diabetes, lupus, rheumatoid arthritis and inflammatory bowel disease. However, Kelty's team noted that "these conditions are rare and are commonly diagnosed later in childhood," so definite conclusions can't be drawn from this study. All of these findings highlight "the importance of further study of opioid-induced immune changes during pregnancy [and] the potential impact on long-term health in exposed children," the authors wrote. Sources JAMA Network Open, Jan. 17, 2024 Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions. Posted January 2024 More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals Subscribe to our newsletter Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.